Drug Approval | September 11, 2024
USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
The USFDA has issued 5 observations pursuant to the completion of audit
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
FDA has concluded that this inspection is 'closed'
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Subscribe To Our Newsletter & Stay Updated
